Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q1

4574.TEDINET S100TDKT
Period2024-01-01 → 2024-03-31
Filed2024-05-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥1.4bn2024-01-01 → 2024-03-31Cons.Net sales
Revenue¥6.1bn2023-01-01 → 2023-12-31Cons.Net sales (5-year summary)
Revenue¥1.2bn2023-01-01 → 2023-03-31Cons.Net sales
Operating income¥214m2024-01-01 → 2024-03-31Cons.Operating income
Operating income−¥155m2023-01-01 → 2023-03-31Cons.Operating income
Ordinary income¥229m2024-01-01 → 2024-03-31Cons.Ordinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥242m2023-01-01 → 2023-03-31Cons.Ordinary income
Profit before tax¥429m2024-01-01 → 2024-03-31Cons.Income before income taxes
Profit before tax−¥242m2023-01-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)¥472m2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥3.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥243m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income¥472m2024-01-01 → 2024-03-31Cons.Profit loss
Net income−¥243m2023-01-01 → 2023-03-31Cons.Profit loss
Total assets¥13.0bnat 2024-03-31Cons.Assets
Total assets¥13.2bnat 2023-12-31Cons.Assets
Total assets¥14.4bnat 2023-03-31Cons.Total assets (5-year summary)
Total liabilities¥5.6bnat 2024-03-31Cons.Liabilities
Total liabilities¥6.5bnat 2023-12-31Cons.Liabilities
Net assets / equity¥7.4bnat 2024-03-31Cons.Net assets
Net assets / equity¥6.7bnat 2023-12-31Cons.Net assets
Net assets / equity¥7.9bnat 2023-03-31Cons.Net assets (5-year summary)
Cash and deposits¥5.2bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥5.5bnat 2023-12-31Cons.Cash and deposits
EPS (basic)¥9.412024-01-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-76.252023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.592023-01-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio57.1%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio51.0%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio54.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-03-31−¥207m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥140m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥140m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥64m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue2024-01-01 → 2024-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue external2024-01-01 → 2024-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentsegment profit2024-01-01 → 2024-03-31−¥2m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥1.2bn
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥1.2bn
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-03-31¥489m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-03-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-03-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-03-31¥421m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥241m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥259m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥259m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-03-31−¥124m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue2023-01-01 → 2023-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue external2023-01-01 → 2023-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentsegment profit2023-01-01 → 2023-03-31−¥5m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥906m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥906m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-03-31¥215m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-03-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-03-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-03-31¥85m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 353
ItemContextValueUnit
Net salesPrior1YTDDuration1167000000JPY
Net salesCurrentYTDDuration1377000000JPY
Cost of salesPrior1YTDDuration593000000JPY
Cost of salesCurrentYTDDuration578000000JPY
Gross profitPrior1YTDDuration574000000JPY
Gross profitCurrentYTDDuration799000000JPY
Selling general and administrative expensesPrior1YTDDuration729000000JPY
Selling general and administrative expensesCurrentYTDDuration584000000JPY
Operating incomePrior1YTDDuration-155000000JPY
Operating incomeCurrentYTDDuration214000000JPY
Interest income noiPrior1YTDDuration4000000JPY
Interest income noiCurrentYTDDuration8000000JPY
Foreign exchange gains noiPrior1YTDDuration－JPY
Foreign exchange gains noiCurrentYTDDuration11000000JPY
Restoration contribution income noiPrior1YTDDuration9000000JPY
Restoration contribution income noiCurrentYTDDuration－JPY
Other noiPrior1YTDDuration2000000JPY
Other noiCurrentYTDDuration4000000JPY
Non operating incomePrior1YTDDuration15000000JPY
Non operating incomeCurrentYTDDuration25000000JPY
Interest expenses noePrior1YTDDuration2000000JPY
Interest expenses noeCurrentYTDDuration2000000JPY
Rent expenses noePrior1YTDDuration0JPY
Rent expenses noeCurrentYTDDuration4000000JPY
Foreign exchange losses noePrior1YTDDuration7000000JPY
Foreign exchange losses noeCurrentYTDDuration－JPY
Commission fee noePrior1YTDDuration12000000JPY
Commission fee noeCurrentYTDDuration3000000JPY
Plant shutsdown related costs noePrior1YTDDuration79000000JPY
Plant shutsdown related costs noeCurrentYTDDuration－JPY
Other noePrior1YTDDuration0JPY
Other noeCurrentYTDDuration0JPY
Non operating expensesPrior1YTDDuration102000000JPY
Non operating expensesCurrentYTDDuration10000000JPY
Ordinary incomePrior1YTDDuration-242000000JPY
Ordinary incomeCurrentYTDDuration229000000JPY
Compensation income eiPrior1YTDDuration－JPY
Compensation income eiCurrentYTDDuration200000000JPY
Extraordinary incomePrior1YTDDuration－JPY
Extraordinary incomeCurrentYTDDuration200000000JPY
Income before income taxesPrior1YTDDuration-242000000JPY
Income before income taxesCurrentYTDDuration429000000JPY
Income taxes currentPrior1YTDDuration4000000JPY
Income taxes currentCurrentYTDDuration18000000JPY
Income taxes deferredPrior1YTDDuration-3000000JPY
Income taxes deferredCurrentYTDDuration-61000000JPY
Income taxesPrior1YTDDuration1000000JPY
Income taxesCurrentYTDDuration-42000000JPY
Profit lossPrior1YTDDuration-243000000JPY
Profit lossCurrentYTDDuration472000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass